The RECAP2 Study: Midazolam and Psilocybin
This triple-blind, randomised, placebo-controlled trial (n=60) will study the role of neuroplasticity in the behavioural effects of psilocybin in individuals with mild declines in emotional wellbeing. Participants will receive one of four medication combinations (25 mg or 1 mg psilocybin with IV midazolam or IV saline).
Details
The study randomises 60 participants to one of four parallel arms combining higher- or very-low-dose psilocybin (25 mg or 1 mg, oral) with either IV midazolam or IV saline; the primary aim is to probe neuroplasticity mechanisms underlying behavioural effects.
Assessments include MRI, TMS, EEG and questionnaires to measure neural and behavioural markers of wellbeing; midazolam is used to induce amnesia of the psychedelic experience without oversedation.